RxDoctor Payments Data

Michael Sims, MD

Family Medicine · Grand Prairie, TXNPI 1336114313

Payments from drug & device makers

$13,768in general payments, 2019–2025

Across 744 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • Biohaven Pharmaceutical Holding Company Ltd.$1K
  • Lilly USA, LLC$1K
  • GSK$966
  • AstraZeneca$924
  • plus $6K from 46 others

What the payments were for

  • Consulting fees$8006%
  • Travel & lodging$3282%
  • Food & beverage$12,62892%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,768 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$47,730
Medicare patients
100
Services billed
633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin41$56,772
TrulicityDulaglutide24$52,656
RybelsusSemaglutide21$45,253
MounjaroTirzepatide27$37,436
FarxigaDapagliflozin Propanediol28$29,599
OzempicSemaglutide30$28,676
Tresiba Flextouch U-200Insulin Degludec26$22,446
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$20,305
Xigduo XrDapaglifloz Propaned/Metformin16$18,271
EliquisApixaban13$8,551
Combivent RespimatIpratropium/Albuterol Sulfate12$6,022
Rosuvastatin Calcium294$2,157
Fluticasone Propionate88$1,810
Olmesartan Medoxomil107$1,626
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide28$1,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,094$90,09351 claims
Novo NordiskRybelsus, Ozempic$1,604$73,92951 claims
Boehringer IngelheimJardiance, Combivent Respimat$831$62,79553 claims
AstraZenecaFarxiga$924$29,59928 claims
GSKTrelegy Ellipta$966$20,30515 claims
PfizerEliquis$733$8,55113 claims
AbbVieSynthroid$1,584$67211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Grand Prairie

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →